Chemistry:LME-54

From HandWiki

LME-54, or simply LME, also known as lysergic acid methylethylamide or as N-methyl-N-ethyllysergamide, is a serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD; LSD-25).[1][2][3][4][5] It is the analogue of LSD in which one of the N-ethyl groups has been replaced with an N-methyl group.[1][2][3]

The drug was tested in humans at a dose of 25 μg and was found to produce no effects at this dose in several subjects and to produce weaker effects than a 25 μg dose of LSD in one subject.[5] Higher doses do not appear to have been assessed.[5] Based on these findings, LME-54 has been described as weakly active or active but less so than LSD with no specific numbers available.[1][2][3][4][6][7] Its antiserotonergic activity in vitro does not appear to have been reported.[6]

LME-54 was first described in the scientific literature by Harold Alexander Abramson and Andre Rolo by 1965.[5][8] It is not a controlled substance in Canada as of 2025.[9]

See also

  • Substituted lysergamide
  • Lysergic acid methylpropylamide (LMP-55)
  • lysergic acid ethylpropylamide (LEP-57)
  • Lysergic acid ethylamide (LAE-32)

References

  1. ↑ 1.0 1.1 1.2 "Psychotomimetic Agents". Psychopharmacological Agents: Use, Misuse and Abuse. Medicinal Chemistry: A Series of Monographs. 4. Academic Press. 1976. pp. 59–146. doi:10.1016/b978-0-12-290559-9.50011-9. ISBN 978-0-12-290559-9. https://bitnest.netfirms.com/external/10.1016/B978-0-12-290559-9.50011-9. 
  2. ↑ 2.0 2.1 2.2 "Hallucinogens". Burger's Medicinal Chemistry. 3 (4 ed.). New York: Wiley. 1980. pp. 1109–1137. ISBN 978-0-471-01572-7. OCLC 219960627. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=6ac0c892ee380436f614d3aae0686ef617b2e0c5. 
  3. ↑ 3.0 3.1 3.2 "Chemistry of Psychotomimetics". Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs. Handbook of Experimental Pharmacology. 55. Berlin: Springer Berlin Heidelberg. 1982. pp. 3–29. doi:10.1007/978-3-642-67770-0_1. ISBN 978-3-642-67772-4. OCLC 8130916. https://bitnest.netfirms.com/external/10.1007/978-3-642-67770-0_1. 
  4. ↑ 4.0 4.1 "Basic Pharmacology and Effects". Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. 2003. pp. 67–137. ISBN 978-0-12-433951-4. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=6bb3a7499da8e9852b39cd4db16891147c83f5c6. Retrieved 1 February 2025. 
  5. ↑ 5.0 5.1 5.2 5.3 "Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects". The Journal of Asthma Research 3 (1): 81–96. September 1965. doi:10.3109/02770906509106904. PMID 5318626. 
  6. ↑ 6.0 6.1 "Stereoselective aspects of hallucinogenic drug action and drug discrimination studies of entactogens". Purdue University. May 1989. https://bitnest.netfirms.com/external/Theses/Oberlender1989. "Table 2. Relative potency values for lysergic acid amides. [...]" 
  7. ↑ "Lysergamides revisited". NIDA Research Monograph 146: 52–73. 1994. PMID 8742794. https://archives.nida.nih.gov/sites/default/files/monograph146.pdf#page=57. "TABLE 2. Relative human potency of lysergic acid amides [...]". 
  8. ↑ "Comparison of LSD with Methysergide and Psilocybin on Test Subjects". The Use of LSD in Psychotherapy and Alcoholism: The Second International Conference on the Use of LSD in Psychotherapy and Alcoholism, May 8th–May 10th, 1965. Indianapolis: The Bobbs-Merill Company. 1967. pp. 53–73. OCLC 302168. https://www.samorini.it/doc1/alt_aut/ad/abramson-the-use-of-lsd-in-psychotherapy-and-alcoholism.pdf#page=70. 
  9. ↑ "Controlled Drugs and Substances Act". https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:LME-54&oldid=4243429"